EVENTS:   Best Equity Short Ideas Conference Call 12 - Zach Shannon/Corto Capital Advisors & Craig Huber/Huber Research Partners & Thomas Beevers /Forensic Alpha & Ed Steele/Iron Blue Financials & Bill Campbell/Paragon Intel - 12 Nov 25   Will AI Deflate the World? Macro Lessons from Three Industrial Revolutions and China - Manoj Pradhan/Talking Heads Macro - 13 Nov 25     ROADSHOWS: Forest Products Sector Equity and Commodity Research With Expertise in Distressed Debt - Kevin Mason /ERA Research   •   London   12 - 14 Nov 25       Buyside to Buyside Forum and Expert Calls across TMT, Consumer, Healthcare and Fintech - Andrew Peters /Revelare Partners   •   London   17 - 19 Nov 25       Fundamental US Healthcare Short Ideas - Dr Elliot Favus /Favus Institutional Research   •   London   17 - 19 Nov 25      

Fortnightly Publication Highlighting Latest Insights From IRF Providers

Company Research

Event-Driven Legal℠ investment-research opportunities

MDC Financial Research

MDC follows significant legal disputes to provide clients with actionable investment ideas that tend to be non-correlated with the market. They currently believe that the following companies will likely be involved in significant litigation in 2025 and 2026: Abbott Laboratories, Avadel Pharmaceuticals, Axsome Therapeutics, Bausch Health, Bayer, Burford Capital, Corcept Therapeutics, Exelixis, GSK, Harmony Biosciences, Johnson & Johnson, Liquidia, Live Nation, Reckitt and Sotera Health.

Edition: 205

- 21 February, 2025


Corcept Therapeutics (CORT)

Healthcare

Favus Institutional Research

Elliot Favus sees CORT being forced to “wind down” over the coming months - his earlier research revealed how the company's salesforce was paying doctors (who had no business receiving any money) substantial amounts to prescribe its drug for treatment outside of the exceedingly rare medical condition for which it is approved. Since then a Federal criminal investigation has begun, but Elliot believes the Street is misreading the nature of the investigation - he expects the prescribers who have been “bribed” to be targeted, and once this happens, CORT’s prescriber base will rapidly disappear along with its revenues.

Edition: 150

- 09 December, 2022